Oncology and Hematology - Global Oncology Academy

529-544 of 804

First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
William J. Gradishar, MD; Erica L. Mayer, MD, MPH
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
1.25 program credits
- Alan Venook, MD
1.25 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Ben Park, MD, PhD
- Ben Park, MD, PhD
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer
Susana Campos, MD, MPH; Nicoletta Colombo, MD
1.00 credit 10 episodes
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
- Ritu Salani, MD
1.00 credit 10 episodes
Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches
Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches
Project Oncology®
Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches
Rachelle W. Johnson, PhD
- Rachelle W. Johnson, PhD

34/11